ECI830 is a highly potent and selective oral small-molecule CDK2 inhibitor. By inhibiting CDK2 activity, ECI830 induces G1/S phase cell cycle arrest, thereby blocking DNA replication and tumor proliferation. ECI830 is suitable for use in studies of HR+/HER2- breast cancer and tumors with CCNE1 amplification.
Molecular Weight:
384.43
CAS Number:
[3054692-62-2]
Formula:
C19H24N6O3
Target:
CDK
T204836
* VAT and and shipping costs not included. Errors and price changes excepted